Literature DB >> 1903327

Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse.

G G Gonzalez1, C V Byus.   

Abstract

Polyamine synthesis is required in normal or neoplastic tissues if they are to continue to grow or divide. The highly inducible enzyme ornithine decarboxylase (ODC) catalyzes the conversion of ornithine to putrescine as the initial step in polyamine biosynthesis. The level of substrate pools of ornithine in cultured cells has been reported to markedly alter mitogen-induced ODC activity, putrescine accumulation, and DNA synthesis (V. Wu and C. V. Byus, Biochim. Biophys. Acta, 804: 89-99, 1984; V. Wu et al., Cancer Res., 41: 3384-3391, 1981). We attempted to limit the amount of ornithine available for polyamine biosynthesis in an animal by using a dietary approach. Since arginine serves as one of the intermediate biosynthetic precursors of ornithine, female CD-1 mice were placed on a special synthetic amino acid diet deficient in arginine. The ability of this arginine-free diet to alter epidermal ornithine and polyamine metabolism and tumorigenesis was assessed in the mouse two-stage model of skin carcinogenesis. The basal level of ornithine in the epidermis in control animals receiving the amino acid complete diet was very high compared to other tissues (155 nmol/mg protein). However, when the mice were fed the isocaloric arginine-free diet for a 2-week period, the levels of epidermal ornithine and arginine decreased by 40% (P less than 0.01). This reduction was blocked by the addition of 2% ornithine to the drinking water of the arginine-restricted animals. Acute administration of 12-O-tetradecanoyl-phorbol-13-acetate (TPA) to the epidermis caused a transient (4 and 8 h) reduction in ornithine and arginine but not lysine in the animals receiving the control, and ornithine-supplemented diets. The animals fed the special arginine-free diet exhibited a 40-50% reduction in tumor multiplicity or papillomas/mouse (P less than 0.05) and had a significantly lower tumor incidence or percentage of animals with tumour throughout a 19-week promotion period (P less than 0.02). However, the major effect of arginine restriction was consistent with an increase in tumor latency. The addition of ornithine completely reversed the reduction in the rate and extent of tumorigenesis in the arginine-free animals. The accumulation of putrescine (but not spermidine or spermine) in the epidermis following a single administration of TPA was significantly reduced in the animals receiving the arginine-free diet. The papillomas or tumors from the animals deprived of arginine had markedly reduced (less than 35%) levels of putrescine compared to the tumors from control animals, and appeared to be more sensitive to dietary arginine restriction than was the chronically promoted but untransformed epidermis.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903327

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.

Authors:  Tawnya L Bowles; Randie Kim; Joseph Galante; Colin M Parsons; Subbulakshmi Virudachalam; Hsing-Jien Kung; Richard J Bold
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

Review 2.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

3.  Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity.

Authors:  Nina Mayorek; Nili Naftali-Shani; Myriam Grunewald
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

Review 4.  Arginine deprivation as a targeted therapy for cancer.

Authors:  L Feun; M You; C J Wu; M T Kuo; M Wangpaichitr; S Spector; N Savaraj
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer.

Authors:  Yan-Shen Shan; Hui-Ping Hsu; Ming-Derg Lai; Meng-Chi Yen; Yi-Pey Luo; Yi-Ling Chen
Journal:  Oncol Rep       Date:  2014-10-20       Impact factor: 3.906

6.  Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.

Authors:  Dong-Joo Cheon; Ann E Walts; Jessica A Beach; Jenny Lester; John S Bomalaski; Christine S Walsh; W Ruprecht Wiedemeyer; Beth Y Karlan; Sandra Orsulic
Journal:  J Pathol Clin Res       Date:  2014-11-05

7.  Oncogene-Selective Sensitivity to Synchronous Cell Death following Modulation of the Amino Acid Nutrient Cystine.

Authors:  Ioannis Poursaitidis; Xiaomeng Wang; Thomas Crighton; Christiaan Labuschagne; David Mason; Shira L Cramer; Kendra Triplett; Rajat Roy; Olivier E Pardo; Michael J Seckl; Scott W Rowlinson; Everett Stone; Richard F Lamb
Journal:  Cell Rep       Date:  2017-03-14       Impact factor: 9.423

8.  Gastric Adenocarcinomas and Signet-Ring Cell Carcinoma: Unraveling Gastric Cancer Complexity through Microbiome Analysis-Deepening Heterogeneity for a Personalized Therapy.

Authors:  Gloria Ravegnini; Bruno Fosso; Viola Di Saverio; Giulia Sammarini; Federica Zanotti; Giulio Rossi; Monica Ricci; Federica D'Amico; Giorgia Valori; Antonella Ioli; Silvia Turroni; Patrizia Brigidi; Patrizia Hrelia; Sabrina Angelini
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

9.  Well differentiated arginase-1 negative hepatocellular carcinoma.

Authors:  Ifeyinwa E Obiorah; Joeffrey Chahine; Byoung Uk Park; Kyungmin Ko; Jose deGuzman; Bhaskar Kallakury
Journal:  Transl Gastroenterol Hepatol       Date:  2019-09-03

10.  Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism.

Authors:  H Takaku; M Matsumoto; S Misawa; K Miyazaki
Journal:  Jpn J Cancer Res       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.